Hematological Malignancies

12
Pipeline Programs
12
Companies
12
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
2
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Cell Therapy
133%
+ 10 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Galapagos
Galapagos2800 MECHELEN, Belgium
1 program
1
GLPG CAR T-cell therapyPhase 3Cell Therapy1 trial
Active Trials
NCT06652633Recruiting546Est. Jul 2039
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD9829Phase 1/21 trial
Active Trials
NCT06179511Active Not Recruiting56Est. Mar 2026
DS
Daiichi SankyoChina - Shanghai
1 program
1
DS3790aPhase 1/21 trial
Active Trials
NCT07220616Recruiting420Est. Nov 2030
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
MagrolimabPhase 1Monoclonal Antibody
MagrolimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03248479Terminated258Est. Sep 2023
H
HutchmedChina - Hong Kong
1 program
1
HMPL-506Phase 11 trial
Active Trials
NCT06387082Recruiting132Est. Dec 2027
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-248Phase 11 trial
Active Trials
NCT05728658Recruiting191Est. Oct 2026
Karyopharm Therapeutics
1 program
1
KPT-330Phase 11 trial
Active Trials
NCT01607892CompletedEst. Oct 2015
CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
1 program
1
MKC-1Phase 11 trial
Active Trials
NCT00506402CompletedEst. Apr 2009
Teva
TevaIsrael - Petach Tikva
1 program
1
Obatoclax mesylatePhase 11 trial
Active Trials
NCT00438178Completed44
Novartis
NovartisBASEL, Switzerland
1 program
1
Study Part 1: KRP203Phase 11 trial
Active Trials
NCT01830010Completed23Est. Aug 2018
CT
1 program
1
TQB3820 tabletsPhase 11 trial
Active Trials
NCT05020639UnknownEst. Dec 2024
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
Weighted BlanketN/A1 trial
Active Trials
NCT06584955Active Not RecruitingEst. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GalapagosGLPG CAR T-cell therapy
Daiichi SankyoDS3790a
AstraZenecaAZD9829
HutchmedHMPL-506
InnoCareICP-248
Chia Tai TianQing Pharmaceutical GroupTQB3820 tablets
Gilead SciencesMagrolimab
NovartisStudy Part 1: KRP203
Karyopharm TherapeuticsKPT-330
CASI PharmaceuticalsMKC-1
TevaObatoclax mesylate
Angel PharmaceuticalsWeighted Blanket

Clinical Trials (12)

Total enrollment: 1,670 patients across 12 trials

NCT06652633GalapagosGLPG CAR T-cell therapy

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Start: Sep 2024Est. completion: Jul 2039546 patients
Phase 3Recruiting
NCT07220616Daiichi SankyoDS3790a

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Start: Jan 2026Est. completion: Nov 2030420 patients
Phase 1/2Recruiting
NCT06179511AstraZenecaAZD9829

Study of AZD9829 in CD123+ Hematological Malignancies

Start: Jan 2024Est. completion: Mar 202656 patients
Phase 1/2Active Not Recruiting
NCT06387082HutchmedHMPL-506

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Start: May 2024Est. completion: Dec 2027132 patients
Phase 1Recruiting
NCT05728658InnoCareICP-248

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Start: Mar 2023Est. completion: Oct 2026191 patients
Phase 1Recruiting
NCT05020639Chia Tai TianQing Pharmaceutical GroupTQB3820 tablets

A Study of TQB3820 in Patients With Hematological Malignancies

Start: Aug 2021Est. completion: Dec 2024
Phase 1Unknown
NCT03248479Gilead SciencesMagrolimab

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Start: Sep 2017Est. completion: Sep 2023258 patients
Phase 1Terminated
NCT01830010NovartisStudy Part 1: KRP203

A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Start: Jun 2013Est. completion: Aug 201823 patients
Phase 1Completed
NCT01607892Karyopharm TherapeuticsKPT-330

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Start: Jul 2012Est. completion: Oct 2015
Phase 1Completed
NCT00506402CASI PharmaceuticalsMKC-1

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Start: Nov 2006Est. completion: Apr 2009
Phase 1Completed
NCT00438178TevaObatoclax mesylate

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

Start: Oct 200544 patients
Phase 1Completed
NCT06584955Angel PharmaceuticalsWeighted Blanket

Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies

Start: May 2025Est. completion: Jul 2027
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 1,670 patients
12 companies competing in this space